CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Nicotinamide ribosideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug868 Escin Wiki 1.00
drug3012 standard therapy Wiki 0.58
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19

The purpose of this study is to investigate whether nicotinamide riboside supplementation can attenuate the severity of SARS-CoV-2 infections in elderly patients. A major event in aging is the loss of the central metabolite nicotinamide adenine dinucleotide (NAD+) that appear to be important in the proinflammatory environment that occur during aging. Notably, recent work from our and other groups suggest that aging can be ameliorated by even a short-term treatment of the NAD+ precursor nicotinamide riboside. Nicotinamide riboside has recently been shown to be able to return aging tissues to a younger state even after short term treatment. This vitamin B3- analog is naturally occurring, is readily taken up through oral administration and has been tested in human trials with few side effects. In this randomized double blinded case-control trial, the investigators will treat elderly (>70 year old) COVID19 patients with 1 g of nicotinamide riboside (NR-E) or placebo for 2 weeks and investigate if this affects the clinical course of the disease.

NCT04407390 COVID Dietary Supplement: Nicotinamide riboside Dietary Supplement: Placebo

Primary Outcomes

Description: Hypoxic respiratory failure as defined by need for oxygen therapy

Measure: Hypoxic respiratory failure

Time: Day 1

Description: Hypoxic respiratory failure as defined by need for oxygen therapy

Measure: Hypoxic respiratory failure

Time: Day 7

Description: Hypoxic respiratory failure as defined by need for oxygen therapy

Measure: Hypoxic respiratory failure

Time: Day 14

Description: Hypoxic respiratory failure as defined by need for oxygen therapy

Measure: Hypoxic respiratory failure

Time: Day 90

Secondary Outcomes

Description: Overall mortality

Measure: Mortality

Time: Day 1

Description: Overall mortality

Measure: Mortality

Time: Day 7

Description: Overall mortality

Measure: Mortality

Time: Day 14

Description: Overall mortality

Measure: Mortality

Time: Day 90

Description: Sepsis

Measure: Sepsis

Time: Day 1

Description: Sepsis

Measure: Sepsis

Time: Day 7

Description: Sepsis

Measure: Sepsis

Time: Day 14

Description: Sepsis

Measure: Sepsis

Time: Day 90

Description: Circulatory failure as defined by a need for interventions to support the circulatory system.

Measure: Circulatory failure

Time: Day 1

Description: Circulatory failure as defined by a need for interventions to support the circulatory system.

Measure: Circulatory failure

Time: Day 7

Description: Circulatory failure as defined by a need for interventions to support the circulatory system.

Measure: Circulatory failure

Time: Day 14

Description: Circulatory failure as defined by a need for interventions to support the circulatory system.

Measure: Circulatory failure

Time: Day 90

Description: Days in hospital

Measure: Days in hospital

Time: Day 1

Description: Days in hospital

Measure: Days in hospital

Time: Day 7

Description: Days in hospital

Measure: Days in hospital

Time: Day 14

Description: Days in hospital

Measure: Days in hospital

Time: Day 90

Description: Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.

Measure: NAD levels

Time: Day 1

Description: Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.

Measure: NAD levels

Time: Day 7

Description: Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.

Measure: NAD levels

Time: Day 14

Description: Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.

Measure: NAD levels

Time: Day 90

No related HPO nodes (Using clinical trials)